Agentix Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGTX research report →
Companywww.agentixcorp.com
Agentix Corp. , a clinical development stage company, focuses on the development and commercialization of therapeutics to treat metabolic diseases. Its product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases.
- CEO
- Riazul Huda
- IPO
- 2015
- Employees
- 3
- HQ
- Dana Point, CA, US
Price Chart
Valuation
- Market Cap
- $1.28M
- P/E
- -2.17
- P/S
- 0.00
- P/B
- -0.37
- EV/EBITDA
- -2.27
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 17.76%
- ROIC
- 16.10%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-567,048 · 0.00%
- EPS
- $-0.01 · 0.00%
- Op Income
- $-513,251
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.06
- 52W Low
- $0.02
- 50D MA
- $0.04
- 200D MA
- $0.04
- Beta
- 0.90
- Avg Volume
- 3.31K
Get TickerSpark's AI analysis on AGTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 29, 20 | Puzzo Thomas E | other | 0 |
| Mar 29, 20 | Grays Peak Ventures LLC | buy | 767,000 |
| Feb 24, 20 | Grays Peak Ventures LLC | other | 1,407,000 |
| Mar 29, 20 | Winterhalter Michael | buy | 150,000 |
| Nov 22, 19 | Winterhalter Michael | sell | 10,015 |
| Nov 4, 19 | Grays Peak Ventures LLC | buy | 9,358 |
| Nov 4, 19 | Stevens Scott B | buy | 9,358 |
| Nov 4, 19 | Winterhalter Michael | sell | 8,433 |
| Oct 9, 19 | Stevens Scott B | buy | 4,712 |
| Oct 24, 19 | Stevens Scott B | other | 4,712 |
Our AGTX Coverage
We haven't published any research on AGTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AGTX Report →